The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
null
吃葡萄不吐葡萄皮
忧心的曼凝
闪闪的灵
无极微光
秋风
Maestro_S
嘻嘻哈哈
GingerF
cdercder
学霸业
云曦
Criminology34
369ninja
aaaa
奔跑
牧青
Nole
风吹麦浪
渡人舟
皖公网安备34019202002308
